Subsequently, with the aid of online bioinformatics tools, we discovered that miR-34a, which serves as a connecting carrier, targets both NEAT1 and the 3’-UTR of SIRT1, consistent with the findings of Luo et al., who provided the first proof that a signaling axis involving NEAT1-miR-34a/SIRT1-Wnt/-catenin exists and that it may be exploited to treat colorectal cancer [33]. This evidence concerns the gene NEAT1 and colorectal cancer.